Key result
Bivalirudin shows promise in primary PCI for STEMI, though clinical uncertainties remain.
Why the study?
Bivalirudin is a promising anticoagulation treatment in STEMI patients treated with primary PCI, but several issues regarding its use remain to be discussed.
Population
Patients with STEMI treated with primary PCI
Design
Review article
Authors
Loading...
May warrant caution with bivalirudin in STEMI primary PCI; leaves open optimal anticoagulation strategy.
This review discusses issues related to the use of bivalirudin as an anticoagulation treatment during primary PCI for STEMI.
Koutouzis et al. (2010) studied this question. Bivalirudin is a promising anticoagulation treatment for patients with STEMI undergoing primary PCI, although several issues regarding its clinical use remain to be addressed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: